Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with <b><i>Pneumocystis jirovecii</i></b> Pneumonia-Reference-Cited by-同舟云学术

Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia

Published:2018 Issue:1 Volume:96 Page:52-65
ISSN:0025-7931
Container-title:Respiration
language:en
Short-container-title:Respiration

Author:

Salzer Helmut J.F.,Schäfer Guido,Hoenigl Martin,Günther Gunar,Hoffmann Christian,Kalsdorf Barbara,Alanio Alexandre,Lange Christoph

Publisher

S. Karger AG

Subject

Pulmonary and Respiratory Medicine

Reference69 articles.

1. Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA: Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000–2010. J Infect Dis 2016; 214: 862–872.

2. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT; HOPS Investigators: AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 2010; 24: 1549–1559.

3. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H: Is it safe to discontinue primary Pneumocystis jirovecii pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count c; 200 cells/microL? Clin Infect Dis 2010; 51: 611–619.

4. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(suppl 1):S5–S14.

5. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F: Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 2009; 136: 190–197.

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunocompetent Patient Co-Infected with COVID-19 and Non-HIV Severe Pneumocystis jirovecii Pneumonia;Emerging Infectious Diseases;2024-09

2. Development of RPA-Cas12a assay for rapid and sensitive detection of Pneumocystis jirovecii;BMC Microbiology;2024-08-26

3. Protective innate immunity against Pneumocystis does not require Stat6-dependent macrophage polarization;Infection and Immunity;2024-08-16

4. A Mathematical Model for the Co-infection Dynamics of Pneumocystis Pneumonia and HIV/AIDS with Treatment;Science Journal of Applied Mathematics and Statistics;2024-07-27

5. Designing an mRNA Vaccine against P. jirovecii Involved in Fatal Pneumonia Infections via Comparative Proteomics and Reverse Vaccinology Approaches;Frontiers in Bioscience-Landmark;2024-07-03